Key Points
- CEO Alexandria Forbes sold 62,000 shares for $523,900 at an average price of $8.45 under a pre-arranged Rule 10b5-1 plan. She retained 1,239,595 shares; the sale reduced her position by 4.76%.
- MeiraGTx’s latest quarter fell short of expectations, reporting a loss of $0.53 per share versus analysts’ $0.50 loss estimate and revenue of $4.81 million versus $6.95 million expected.
- Analyst views are mixed: the consensus rating is “Moderate Buy” with a $24 price target, while HC Wainwright lowered its 2026 and 2027 earnings forecasts.
MeiraGTx Holdings PLC (NASDAQ:MGTX - Get Free Report) CEO Alexandria Forbes sold 62,000 shares of the firm's stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $8.45, for a total value of $523,900.00. Following the completion of the sale, the chief executive officer directly owned 1,239,595 shares of the company's stock, valued at $10,474,577.75. The trade was a 4.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
MeiraGTx Stock Down 3.2%
Shares of MGTX stock opened at $8.46 on Wednesday. The stock's fifty day moving average price is $10.51 and its 200 day moving average price is $10.37. MeiraGTx Holdings PLC has a 1-year low of $6.62 and a 1-year high of $15.35. The company has a market cap of $826.80 million, a price-to-earnings ratio of 10.58 and a beta of 1.09. The company has a debt-to-equity ratio of 0.57, a current ratio of 4.62 and a quick ratio of 4.62.
MeiraGTx (NASDAQ:MGTX - Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by ($0.03). MeiraGTx had a net margin of 19.46% and a return on equity of 85.23%. The business had revenue of $4.81 million during the quarter, compared to analysts' expectations of $6.95 million. On average, research analysts expect that MeiraGTx Holdings PLC will post 0.20 earnings per share for the current fiscal year.
Key Headlines Impacting MeiraGTx
Investors following MGTX have been watching these headlines:
- Positive Sentiment: MeiraGTx announced an oral presentation of its AAV-BDNF program for severe early-onset obesity at ObesityWeek 2026. The presentation could increase visibility for the program, though the announcement itself does not report new clinical results. Article: MeiraGTx oral presentation announcement
- Negative Sentiment: HC Wainwright lowered its earnings estimates across 2026 and 2027. It cut its FY2026 EPS forecast to $0.10 from $0.36 and its FY2027 forecast to a loss of $1.83 per share from a loss of $1.45, also reducing estimates for each quarter from Q4 2026 through Q4 2027. The broader downward revisions may weigh on expectations for profitability. MarketBeat MGTX coverage
Institutional Investors Weigh In On MeiraGTx
Institutional investors and hedge funds have recently modified their holdings of the company. Johnson & Johnson purchased a new stake in MeiraGTx in the second quarter valued at approximately $89,720,775. BlackRock Inc. acquired a new position in MeiraGTx in the 2nd quarter worth approximately $64,269,000. Opaleye Management Inc. raised its position in MeiraGTx by 67.2% during the 2nd quarter. Opaleye Management Inc. now owns 3,550,000 shares of the company's stock worth $47,960,000 after buying an additional 1,426,741 shares during the last quarter. Rubric Capital Management LP raised its position in MeiraGTx by 13.4% during the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock worth $60,620,000 after buying an additional 824,669 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in MeiraGTx by 250.3% during the 3rd quarter. Goldman Sachs Group Inc. now owns 1,147,015 shares of the company's stock worth $12,617,000 after buying an additional 819,599 shares during the last quarter. Institutional investors and hedge funds own 67.48% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on the company. The Goldman Sachs Group began coverage on MeiraGTx in a research note on Thursday, September 24th. They set a "neutral" rating and a $16.00 price target on the stock. Royal Bank Of Canada upped their target price on MeiraGTx from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Friday, August 14th. Zacks Research lowered MeiraGTx from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 11th. Weiss Ratings lowered MeiraGTx from a "hold (c+)" rating to a "hold (c)" rating in a research note on Friday. Finally, Wall Street Zen cut MeiraGTx from a "buy" rating to a "hold" rating in a research report on Saturday. Five equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $24.00.
View Our Latest Report on MGTX
About MeiraGTx
(
Get Free Report)
MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].